ALT vs NVO: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NVO is the larger of the two ($178.19B market cap): the incumbent the market prices for continued execution (11.94x forward earnings, beta 0.37). ALT is the smaller challenger ($390.98M), priced similarly on forward earnings (-3.01x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ALT vs NVO: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ALT | NVO | What it tells you |
|---|---|---|---|
| Market cap | $390.98M | $178.19B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -3.01 | 11.94 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.15 | 0.37 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 2% of range | 18% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 0.82 | 5.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ALT and NVO affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALT and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALT and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Altimmune (ALT) do?
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Its lead candidate, pemvidutide, is a dual agonist of the GLP-1 and glucagon receptors designed to drive weight loss while preserving lean mass and improving liver health. The company has run a Phase 2 obesity program (MOMENTUM) and a Phase 2b MASH program (IMPACT), and reported positive 48-week topline MASH results in December 2025 showing significant improvements in liver fat, weight, and fibrosis markers versus placebo. On the strength of IMPACT, pemvidutide received FDA Breakthrough Therapy Designation in MASH.
What does Novo Nordisk (NVO) do?
Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.
ALT vs NVO: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ALT drivers: Differentiated GLP-1/glucagon profile; MASH opportunity.
- NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year.
ALT or NVO: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALT if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALT and NVO guides.
ALT vs NVO: the full fundamentals
ALT. As a pre-revenue biotech, Altimmune cannot be valued on earnings or P/E; its market value reflects the probability-weighted commercial potential of pemvidutide. At about $446 million the market cap now sits below the roughly $519 million of cash and investments and under book value, which means the market is assigning little or negative value to the pipeline despite Breakthrough and Fast Track designations. Nine analysts carry a mean target near $17, far above the price, and the next quarterly report is expected around November 5, 2026.
NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9x trailing and 11x forward earnings in October 2026 it now trades at a discount that reflects slowing sales and share loss to Eli Lilly. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; Q3 2026 results are due November 4.
Headline figures (approximate, October 2026): ALT shows product revenue None (clinical-stage), cash and investments (jun 30, 2026) ~$519 million, net loss (ttm) ~$92 million, eps (q2 2026 actual vs est.) ~-$0.12 vs ~-$0.12; NVO shows revenue (ttm) ~DKK 329 billion (+2% YoY in Q2 2026), revenue (2026 consensus) ~DKK 301 billion, operating margin (ttm) ~43%, net margin (ttm) ~35%.
The bottom line: ALT vs NVO
ALT and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALT and NVO exposure against your real portfolio. It is not an investment adviser.
Wondering how ALT or NVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Altimmune
Ask Walnut's AI anything about ALT and see how it fits what you own.
FAQ
What is the difference between ALT and NVO?
+
Altimmune is a clinical-stage biopharmaceutical company focused on metabolic and liver disease. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ALT or NVO the better stock?
+
Neither is universally better. NVO is the larger incumbent; ALT is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ALT or NVO?
+
On forward P/E (as of November 2026), ALT trades at -3.01x and NVO at 11.94x, so ALT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ALT and NVO?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ALT vs NVO?
+
ALT: Altimmune is a single-asset, clinical-stage company with no approved products and no revenue, so a failed or disappointing Phase 3 readout could sharply reduce the stock, and the Phase 3 MASH data are not due until 2029, leaving years of funding needs before that answer arrives. It competes in obesity against Novo Nordisk and Eli Lilly, which have vastly greater scale, marketing, and pipelines. Even positive trials carry regulatory and commercialization risk, and the company will likely need additional capital over a multi-year development path, which can dilute existing shareholders; the April 2026 offering already did so. The share price has fallen to its 52-week low even as the trials advanced, which shows how little near-term support clinical milestones have given the stock. NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 140 billion against about DKK 45 billion of cash at mid-2026).
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ALT or NVO; figures are approximate and dated (as of November 2026). Verify current data before investing.